In Vitro and In Vivo Assessment of Mu opioid receptor constitutive activity

Methods in Enzymology

Volumn 484, Issue C, 2010, Pages 413-443

  Bilsky, Edward J ^a   Giuvelis, Denise ^a   Osborn, Melissa D ^a   Dersch, Christina M ^b   Xu, Heng ^b   Rothman, Richard B ^b  

^a UNIVERSITY OF NEW ENGLAND   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; MU OPIATE RECEPTOR; NALOXONE; OPIATE; OPIATE ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; BOOK; CHO CELL; CHRONIC PAIN; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING; REGULATORY MECHANISM; STRUCTURE ACTIVITY RELATION;

EID: 78049320270     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381298-8.00021-6     Document Type: Chapter

References (38)

1. Aloyo V.J., Berg K.A., Spampinato U., Clarke W.P., Harvey J.A. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors. Pharmacol. Ther. 2009, 121:160-173.
2. Arden J.R., Segredo V., Wang Z., Lameh J., Sadee W. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. J. Neurochem. 1995, 65:1636-1645.
3. Bilsky E.J., Bernstein R.N., Wang Z., Sadée W., Porreca F. Effects of naloxone and D-Phe-Cys-Try-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. J. Pharmacol. Exp. Ther. 1996, 277:484-490.
4. Breivogel C.S., Selley D.E., Childers S.R. Acute and chronic effects of opioids on delta and mu receptor activation of G proteins in NG108-15 and SK-N-SH cell membranes. J. Neurochem. 1997, 68:1462-1472.
5. Compton P., Miotto K., Elashoff D. Precipitated opioid withdrawal across acute physical dependence induction methods. Pharmacol. Biochem. Behav. 2004, 77:263-268.
6. Costa T., Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. 1989, 86:7321-7325.
7. Covel J.A., Santora V.J., Smith J.M., Hayashi R., Gallardo C., Weinhouse M.I., Ibarra J.B., Schultz J.A., Park D.M., Estrada S.A., Hofilena B.J., Pulley M.D., et al. Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activity. J. Med. Chem. 2009, 52:5603-5611.
8. Gold L.H., Stinus L., Inturrisi C.E., Koob G.F. Prolonged tolerance, dependence and abstinence following subcutaneous morphine pellet implantation in the rat. Eur. J. Pharmacol. 1994, 253:45-51.
9. Gray J.A., Sheffler D.J., Bhatnagar A., Woods J.A., Hufeisen S.J., Benovic J.L., Roth B.L. Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells. Mol. Pharmacol. 2001, 60:1020-1030.
10. Harding W.W., Tidgewell K., Byrd N., Cobb H., Dersch C.M., Butelman E.R., Rothman R.B., Prisinzano T.E. Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. J. Med. Chem. 2005, 48:4765-4771.
11. Hazel K.D., Fluck J., Jones N.T., Evola M., Young A.M. Comparison of antagonist potency to evoke an acute withdrawal stimulus 4h after pretreatment with morphine in rats. FASEB J. 2008, 22:712.
12. Jordan B.A., Devi L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999, 399:697-700.
13. Kest B., Palmese C.A., Hopkins E., Adler M., Juni A., Mogil J.S. Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: Evidence for common genetic mechanisms in acute and chronic morphine physical dependence. Neuroscience 2002, 115:463-469.
14. Klee W.A., Nirenberg M. A neuroblastoma times glioma hybrid cell line with morphine receptors. Proc. Natl. Acad. Sci. USA 1974, 71:3474-3477.
15. Liu J.G., Prather P.L. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Mol. Pharmacol. 2001, 60:53-62.
16. Lunn C.A. Updating the chemistry and biology of cannabinoid CB2 receptor-specific inverse agonists. Curr. Top. Med. Chem. 2010, 10:768-778.
17. Nordstedt C., Fredholm B.B. A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Anal. Biochem. 1990, 189:231-234.
18. Osborn M.D., Lowery J.J., Skorput A.G., Giuvelis D., Bilsky E.J. In vivo characterization of the opioid antagonist nalmefene in mice. Life Sci. 2010, 86:624-630.
19. Raehal K.M., Lowery J.J., Bhamidipati C.M., Paolino R.M., Blair J.R., Wang D., Sadee W., Bilsky E.J. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J. Pharmacol. Exp. Ther. 2005, 313:1150-1162.
20. Sadée W., Wang D., Bilsky E.J. Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci. 2005, 76:1427-1437.
21. Sally E.J., Xu H., Dersch C.M., Hsin L.W., Chang L.T., Prisinzano T.E., Simpson D.S., Giuvelis D., Rice K.C., Jacobson A.E., et al. Identification of a novel "almost neutral" mu-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor. Synapse 2009, 64:280-288.
22. Sirohi S., Dighe S.V., Madia P.A., Yoburn B.C. The relative potency of inverse agonists and a neutral opioid antagonist in precipitated withdrawal. J. Pharmacol. Exp. Ther. 2009, 330:513-519.
23. Standifer K.M., Pasternak G.W. G proteins and opioid receptor-mediated signaling. Cell. Signal. 1997, 9:237-248.
24. Toll L., Berzetei-Gurske I.P., Polgar W.E., Brandt S.R., Adapa I.D., Rodriguez L., Schwartz R.W., Haggart D., O'Brien A., White A., et al. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res. Monogr. 1998, 178:440-466.
25. Traynor J.R., Nahorski S.R. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 1995, 47:848-854.
26. Traynor J.R., Clark M.J., Remmers A.E. Relationship between rate and extent of G protein activation: Comparison between full and partial opioid agonists. J. Pharmacol. Exp. Ther. 2002, 300:157-161.
27. Waldhoer M., Bartlett S.E., Whistler J.L. Opioid receptors. Annu. Rev. Biochem. 2004, 73:953-990.
28. Walker E.A., Makhay M.M., House J.D., Young A.M. In vivo pA2 analysis of naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J. Pharmacol. Exp. Ther. 1994, 271:959-968.
29. Wang Z., Bilsky E.J., Porreca F., Sadee W. Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci. 1994, 54:PL339-PL350.
30. Wang D., Raehal K.M., Bilsky E.J., Sadee W. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): Possible role of basal receptor signaling in narcotic dependence. J. Neurochem. 2001, 77:1590-1600.
31. Wang D., Raehal K.M., Lin E.T., Lowery J.J., Kieffer B.L., Bilsky E.J., Sadée W. Basal signaling activity of mu opioid receptor in mouse brain: Role in narcotic dependence. J. Pharmacol. Exp. Ther. 2004, 308:512-520.
32. Wang D., Sun X., Sadée W. Different effects of opioid antagonists on mu, delta-, and kappa-opioid receptors with and without agonist pretreatment. J. Pharmacol. Exp. Ther. 2007, 321:544-552.
33. Way E.L., Loh H.H., Ho I.K., Iwamoto E.T., Wei E. Neuroanatomical and chemical correlates of naloxone-precipitated withdrawal. Adv. Biochem. Psychopharmacol. 1973, 8:455-470.
34. Williams J.T., Christie M.J., Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol. Rev. 2001, 81:299-343.
35. Woods J.H., Winger G., France C.P. Use of in vivo apparent pA2 analysis in assessment of opioid abuse liability. Trends Pharmacol. Sci. 1992, 13:282-286.
36. Xu H., Wang X., Wang J., Rothman R.B. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned mu opioid receptor. Synapse 2004, 52:209-217.
37. Xu H., Partilla J.S., Wang X., Rutherford J.M., Tidgewell K., Prisinzano T.E., Bohn L.M., Rothman R.B. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse 2007, 61:166-175.
38. Yano I., Takemori A.E. Inhibition by naloxone and dependence in mice treated acutely and chronically with morphine. Res. Commun. Chem. Pathol. Pharmacol. 1977, 16:721-734.